Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s814
DOI: 10.25251/hwgx7622 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Richard G. Langley und 15 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction: In patients (pts) with psoriatic arthritis (PsA) in the BE BOLD study, bimekizumab (BKZ; IL-17A/F inhibitor) reported superiority for the joint-focused primary endpoint (≥50% improvement from baseline [BL] in American College of Rheumatology response criteria [ACR50]) compared with risankizumab (RZB; IL-23 inhibitor) at Week (Wk) 16 (49.1% vs 38.4%, p
Zitieren
APA
Langley, R. G., Gottlieb, A. B., Lebwohl, M., Song, E. J., Thaçi, D., Morita, A., Mease, P. J., McInnes, I. B., Gossec, L., Tanaka, Y., Ink, B., Marten, A., Coarse, J., Manente, M., Szilagyi, B., & Merola, J. F. (2026). Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study. SKIN The Journal of Cutaneous Medicine, 10(6), s814. https://doi.org/10.25251/hwgx7622
Vancouver
Langley RG, Gottlieb AB, Lebwohl M, Song EJ, Thaçi D, Morita A, et al. Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s814. doi:10.25251/hwgx7622
BibTeX
@article{Langley2026,
author = {Langley, Richard G. and Gottlieb, Alice B. and Lebwohl, Mark and Song, E. James and Thaçi, Diamant and Morita, Akimichi and Mease, Philip J. and McInnes, Iain B. and Gossec, Laure and Tanaka, Yoshiya and Ink, Barbara and Marten, Alexander and Coarse, Jason and Manente, Myriam and Szilagyi, Balint and Merola, Joseph F.},
title = {Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s814},
doi = {10.25251/hwgx7622}
}
EUVIMED